Percutaneous coronary intervention-related bleeding risk factors in current practice

Annals of Pharmacotherapy

Volumn 39, Issue 10, 2005, Pages 1627-1633

  Mathis, A Scott ^a,b   Gugger, James J ^a  

^a RUTGERS UNIVERSITY   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

Author keywords

Bivalirudin; Glycoprotein IIb IIIa antagonist; Heparin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; CREATININE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ADULT; AGED; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 25844461745     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G057     Document Type: Review

References (25)

1. Milkovich G, Gibson G. Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous intervention. Am J Health Syst Pharm 2003;60(suppl 3):S15-21.
2. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al., for the Replace-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 Randomized Trial. JAMA 2003;289:853-63.
3. Kokolis S, Cavusoglu E, Clark LT, Marmur JD. Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors. Prog Cardiovasc Dis 2004;46:506-23. DOI 10.1016/j.pcad.2004.02.002
4. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, et al., for the Replace-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization. JAMA 2004;292:696-703.
5. Wolfram R, Leborgne L, Cheneau E, Pinnow EE, Canos DA, Hellinga D, et al. Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention. Am J Cardiol 2003;92:1080-3. DOI 10.1016/j.amjcard.2003.06.004
6. Chew DP, Bhatt DL, Kimball W, Henry TD, Berger P, McCullough PA, et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 2003;92:919-23. DOI 10.1016/50002-9149(03)00970-6
7. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003;108:2769-75. DOI 10.1161/01.CIR.0000103623.63687.21
8. Szczech LA, Reddan DN, Owen WF, Califf R, Racz M, Jones RH, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 2001;60:292-9.
9. Pinkau T, Mann JF, Ndrepepa G, Mehilli J, Hadamitzky M, Braun S, et al. Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes. Am J Kidney Dis 2004;4: 627-35. DOI 10.1053/j.ajkd.2004.05.045
10. Gurm HS, Lincoff AM, Kleiman NS, Kereiakes DJ, Tcheng JE, Aronow HD, et al. Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. Am J Cardiol 2004;94:30-4. DOI 10.1016/j.amjcard.2004.03.025
11. Ali A, Hashem M, Rosman HS, Moser L, Rehan A, Davis T, et al. Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients. J Clin Pharmacol 2004;44:1328-32. DOI 10.1177/0091270004269559
12. Villeneuve E, Sunderji R. Glycoprotein IIb/IIIa inhibitors in patients with end-stage renal disease. Ann Pharmacother 2005;39:732-5. Epub 22 Feb 2005. DOI 10.1345/aph.1E365
13. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003;92:930-5. DOI 10.1016/S0002-9149(03)00972-X
14. Piper WD, Malenka DJ, Ryan TJ Jr, Shubrooks SJ Jr, O'Connor GT, Robb JF, et al., for the Northern New England Cardiovascular Disease Study Group. Predicting vascular complications in percutaneous coronary interventions. Am Heart J 2003;145:1022-9. DOI 10.1016/S0002-8703(03)00079-6
15. Konstance R, Tcheng JE, Wightman MB, Kelly LP, Moore A, Harrison JK, et al. Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era. J Interv Cardiol 2004;17:65-70.
16. Assail AR, Moustapha A, Sdringola S, Salloum J, Awadalla H, Saikia S, et al. The dilemma of success: percutaneous coronary interventions in patients > or = 75 years of age-successful but associated with higher vascular complications and cardiac mortality. Catheter Cardiovasc Interv 2003;59:195-9. DOI 10.1002/ccd.10532
17. Wu AH, Goss JR, Maynard C, Stewart DK, Zhao XQ. Predictors of hospital outcomes after percutaneous coronary intervention in the community. J Interv Cardiol 2004;17:151-8.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. Best PJM, Reddan DN, Berger PB, Szczech LA, McCullough PA, Califf RM. Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J 2004;148:230-42. DOI 10.1016/j.ahj.2004.04.011
20. Björklund E, Lindahl B, Stenestrand U, Swahn E, Dellborg M, Pehrsson K, et al., for the Swedish ASSENT-2 and RIKS-HIA Investigators. Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial. Am Heart J 2004;148:566-73. DOI 10.1016/J.ahj.2004. 04.014
21. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Coslo FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004;141: 929-37.
22. Kini AS, Mitre CA, Kamran M, Suleman J, Kim M, Duffy ME, et al. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol 2002;89:999-1002.
23. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
24. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-95.
25. Reddan D, Szczech LA, O'Shea S, Califf RM. Anticoagulation in acute cardiac care patients with chronic kidney disease. Am Heart J 2003;145: 586-94. DOI 10.1067/mhj.2003.168